Citi analyst Joanne Wuensch added an “upside 90-day catalyst watch” on Tandem Diabetes (TNDM) while keeping a Neutral rating on the shares with a $22 price target The firm believes the company’s Q1 report will show continued progress on its reimbursement strategy. The shares could be a “short squeeze” post the print, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
- Truist upgrades Tandem Diabetes to Buy on growing conviction in upside potential
- Tandem Diabetes upgraded to Buy from Hold at Truist
- DraftKings, Eli Lilly downgraded: Wall Street’s top analyst calls
- Tandem Diabetes upgraded to Overweight from Neutral at Piper Sandler